CommercialPrior AuthMedium impact
Leuprolide Mesylate (Camcevi ETM™; Camcevi Kit)
BCBS Tennessee·TN · Oncology, Urology·Medical Policy
Effective date
Dec 1, 2026
We identified it
Sep 10, 2026
Summary
BlueCross BlueShield of Tennessee is establishing a new prior authorization policy for Leuprolide Mesylate (Camcevi ETM™; Camcevi Kit) effective December 1, 2026. The policy covers prostate cancer (FDA-approved) and salivary gland tumors (compendial use) with 12-month authorization periods, requiring documentation of androgen receptor (AR) positive status. Initial and continuation authorizations require clinical benefit assessment.
Action Required
By November 15, 2026: Billing team must implement prior authorization workflow for Leuprolide Mesylate (Camcevi) in the billing system and EMR. (1) Update prior auth requirements to flag all Leuprolide Mesylate claims for prostate cancer and salivary gland tumor diagnoses. (2) Create prior auth submission checklist requiring androgen receptor (AR) positive test results as mandatory documentation. (3) Configure system to grant initial 12-month authorization periods and flag requests for reauthorization when approaching expiration. (4) For prostate cancer continuation, system must verify documentation of clinical benefit (serum testosterone <50 ng/dL) and absence of unacceptable toxicity. (5) For salivary gland tumor continuation, verify no disease progression or unacceptable toxicity. (6) Train billing staff and providers on new requirements. (7) Update encounter templates and prior auth request forms to include AR status documentation field. Failure to obtain prior authorization will result in claim denials.